At present, immune checkpoint therapy targeting Programmed death 1 (PD-1) receptor and its ligand PD-L1 has been approved for the treatment of patients with certain types of malignancies (50).Immunotherapy drugs have shown good anti-tumor activity in patients with advanced NPC or with recurrence or metastasis after failure of standard therapy (51). Here, CD274 is linked to nasopharyngeal carcinoma.